MNKD

+ Watchlist + Portfolio

MannKind Corp.

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.95
52-Week Range: $2.23 – $6.51
Market Cap: $1.22B
P/E (TTM): —
EPS (TTM): -0.14
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: 4.39
Return on Equity: —
Return on Assets: 0.79%
Gross Margin: 75.39%
Operating Margin: -0.76%
Profit Margin: -11.08%
Current Ratio: 1.72
Debt/Equity: —
Total Debt: $433.83M
Free Cash Flow: $40.31M
Revenue Growth: 42.90%
Earnings Growth: —
Enterprise Value: $1.54B

MNKD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$99.77M	$198.96M	$285.50M	$348.97M
Cost of Revenue	$57.50M	$62.77M	$76.60M	$87.96M
Gross Profit	$42.27M	$136.19M	$208.90M	$261.01M
Research & Development	$19.72M	$31.28M	$45.89M	$66.35M
Selling, General & Admin	$91.47M	$94.31M	$94.33M	$144.13M
Operating Expenses	$111.19M	$125.60M	$140.22M	$214.46M
Operating Income	-$68.92M	$10.59M	$68.68M	$46.55M
EBITDA	-$56.32M	$19.11M	$75.66M	$51.51M
Pretax Income	-$87.40M	-$10.38M	$30.52M	$1.41M
Income Tax	$0.00	$1.56M	$2.93M	-$4.46M
Net Income	-$87.40M	-$11.94M	$27.59M	$5.86M
Diluted EPS	-0.34	-0.04	0.10	0.02
Diluted Shares	257.09M	267.01M	283.84M	314.11M

MNKD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$69.77M	$238.48M	$46.34M	$74.88M
Receivables	$16.80M	$14.90M	$11.80M	$38.37M
Inventory	$21.77M	$28.55M	$27.89M	$35.31M
Current Assets	$234.90M	$373.39M	$268.31M	$291.58M
Total Assets	$295.28M	$475.20M	$393.84M	$792.18M
Current Liabilities	$67.30M	$104.13M	$81.84M	$171.03M
Long-Term Debt	$273.49M	$248.70M	$36.05M	$318.36M
Total Debt	$278.83M	$272.62M	$50.12M	$367.44M
Total Liabilities	$545.82M	$721.37M	$472.66M	$843.20M
Retained Earnings	-$3.22B	-$3.23B	-$3.20B	-$3.20B
Shareholders' Equity	-$250.54M	-$246.17M	-$78.82M	-$51.02M
Working Capital	$167.60M	$269.27M	$186.47M	$120.55M
Net Debt	$203.72M	$30.22M	—	$279.76M

MNKD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$80.68M	$34.09M	$42.51M	$18.25M
Capital Expenditure	-$7.59M	-$42.44M	-$9.69M	-$4.57M
Free Cash Flow	-$88.27M	-$8.35M	$32.82M	$13.69M
Depreciation & Amortisation	$6.31M	$4.54M	$7.37M	$12.28M
Stock-Based Compensation	$13.45M	$17.65M	$21.36M	$24.20M
Investing Cash Flow	$4.87M	-$1.99M	-$96.65M	-$304.80M
Financing Cash Flow	$21.39M	$136.61M	-$137.27M	$315.10M
Net Change in Cash	-$54.42M	$168.71M	-$191.40M	$28.55M

MNKD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$78.35M	$76.53M	$82.13M	$111.95M	$90.17M	$109.38M
Cost of Revenue	$17.52M	$20.57M	$20.20M	$29.67M	$17.47M	$29.54M
Gross Profit	$60.84M	$55.96M	$61.93M	$82.28M	$72.70M	$79.83M
Research & Development	$11.02M	$13.68M	$14.06M	$27.59M	$17.23M	$18.00M
Selling, General & Admin	$25.01M	$31.62M	$29.09M	$58.41M	$54.09M	$58.30M
Operating Expenses	$36.04M	$45.30M	$43.15M	$89.97M	$75.68M	$80.67M
Operating Income	$24.80M	$10.66M	$18.78M	-$7.69M	-$2.98M	-$835.00K
EBITDA	$26.85M	$9.70M	$17.92M	-$3.05M	$2.93M	$2.47M
Pretax Income	$13.62M	$940.00K	$7.78M	-$20.93M	-$16.37M	-$19.14M
Income Tax	$459.00K	$272.00K	-$204.00K	-$4.98M	$253.00K	-$106.00K
Net Income	$13.16M	$668.00K	$7.99M	-$15.95M	-$16.62M	-$19.03M
Diluted EPS	0.04	0.00	0.03	-0.05	-0.05	-0.06
Diluted Shares	320.90M	311.48M	311.64M	307.26M	308.27M	309.19M

MNKD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$47.31M	$57.01M	$127.39M	$74.88M	$52.83M	$52.93M
Receivables	$28.90M	$27.14M	$17.38M	$38.37M	$28.14M	$43.21M
Inventory	$28.89M	$28.49M	$26.97M	$35.31M	$49.17M	$44.42M
Current Assets	$273.74M	$279.03M	$358.84M	$291.58M	$251.16M	$245.71M
Total Assets	$410.14M	$411.70M	$494.64M	$792.18M	$744.40M	$732.30M
Current Liabilities	$115.94M	$111.83M	$109.13M	$171.03M	$134.56M	$142.90M
Long-Term Debt	—	—	$73.43M	$318.36M	$318.72M	$319.08M
Total Debt	$47.25M	$46.82M	$119.91M	$367.44M	$330.96M	$330.85M
Total Liabilities	$468.76M	$466.74M	$539.19M	$843.20M	$803.60M	$799.50M
Retained Earnings	-$3.19B	-$3.19B	-$3.18B	-$3.20B	-$3.21B	-$3.23B
Shareholders' Equity	-$58.62M	-$55.04M	-$44.55M	-$51.02M	-$59.20M	-$67.20M
Working Capital	$157.80M	$167.20M	$249.71M	$120.55M	$116.60M	$102.81M
Net Debt	—	—	—	$279.76M	$265.89M	$266.16M

MNKD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$6.38M	$8.95M	$23.64M	-$7.96M	-$5.37M	-$18.37M
Capital Expenditure	-$330.00K	-$1.12M	-$1.13M	-$1.99M	-$1.88M	-$5.08M
Free Cash Flow	-$6.71M	$7.83M	$22.52M	-$9.95M	-$7.25M	-$23.45M
Depreciation & Amortisation	$2.65M	$2.62M	$2.80M	$4.21M	$6.91M	$6.84M
Stock-Based Compensation	$5.38M	$7.52M	$4.32M	$6.97M	$6.46M	$10.23M
Investing Cash Flow	$5.96M	$6.26M	-$25.06M	-$291.96M	$18.73M	$17.91M
Financing Cash Flow	$1.39M	-$5.51M	$71.81M	$247.41M	-$35.41M	$559.00K
Net Change in Cash	$975.00K	$9.70M	$70.39M	-$52.51M	-$22.05M	$97.00K

Market Snapshot

About

MannKind develops and commercializes Afrezza, an inhaled insulin therapy for adults with diabetes. The biopharmaceutical company focuses on Technosphere drug delivery technology for pulmonary administration of therapeutic compounds.